Pioneering a Revolution in Genomic Research: MGI Partners with Xpress Genomics
Aug 9, 2023
Share
In a significant move within the life science industry, MGI, recognized as a global frontrunner in life science technology, has forged a strategic alliance with Xpress Genomics, a pioneering Stockholm-based entity renowned for its advanced RNA-sequencing strategies. This partnership is poised to catapult genomics research into unprecedented territories by integrating state-of-the-art technologies to craft scalable and efficient solutions for deep single-cell RNA-sequencing (scRNA-seq), a technique pivotal for understanding cellular functions in complex biological systems.
About Xpress Genomics
At the helm of Xpress Genomics is Prof. Rickard Sandberg, alongside CEO Dr. Christoph Ziegenhain and a cadre of impassioned researchers. The company has swiftly ascended to the forefront of the industry, championing the development of scalable single-cell RNA-sequencing methodologies. Xpress Genomics stands out for its commitment to maintaining the integrity of quality and coverage, ensuring that its scRNA-seq solutions offer unparalleled sensitivity across entire transcripts. This technological prowess facilitates comprehensive analyses of marker genes, genetic variations, and splicing events, thereby enabling large-scale genomic studies.
Prof. Sandberg's enthusiasm about the collaboration reflects the potential impact of this alliance, "We are thrilled at the prospect of merging our expertise with MGI's sequencing prowess to bring forth the most cost-effective and scalable full-length scRNA-seq solutions to date."
A Partnership with Vision
The synergy between MGI and Xpress Genomics is driven by a mutual ambition to transcend the current limits of single-cell genomics. Duncan Yu, President of MGI, articulated the strategic significance of this collaboration, emphasizing MGI's dedication to equipping the global scientific community with cutting-edge tools that foster industry advancement. Ming Ni, MGI's Vice President, further underscored the transformative nature of single-cell RNA-sequencing and MGI's commitment to supporting Xpress Genomics in overcoming the inherent challenges of single-cell sequencing.
New Laboratory Facility in Sweden
A testament to the solidity of this partnership is the inauguration of a new laboratory facility by Xpress Genomics within the prestigious Cancer Center Karolinska (CCK) in Sweden. This facility is outfitted with MGI's DNBSEQ sequencers, heralding a new era of accessibility to advanced single-cell RNA-seq solutions for local collaborators and partners. Yong Hou, General Manager of MGI Europe and Africa, highlighted the importance of this laboratory in connecting with the local research and diagnostic sectors, thereby fostering novel genomic discoveries and medical innovations.
Important Note
It's crucial to note that StandardMPS and CoolMPS sequencing reagents, along with sequencers designed for these reagents, have specific regional availability constraints. These products are exclusively for Research Use Only and are not intended for diagnostic purposes, with certain geographic exceptions detailed in the official communication from MGI.
About MGI
MGI Tech Co., Ltd. (MGI) is at the forefront of global innovation, actively contributing to life science through intelligent innovation. With a presence in over 100 countries and a customer base of 2600+, MGI's cutting-edge technology has been instrumental in the development of 736+ user patents, facilitating the creation of over 150 petabytes of data. The company's extensive portfolio includes sequencing instruments, automation instruments, reagents, and related products that cater to various sectors such as life science research, agriculture, precision medicine, and healthcare.
MGI is dedicated to advancing life science tools for the healthcare of the future. As of December 2021, the company's global presence has expanded to more than 100 countries and regions, serving over 1,300 international clients. With a workforce of over 2,900 professionals worldwide, including 5 centers for research and development and production facilities in Europe, MGI is committed to fostering innovation. Approximately 35% of MGI's employees are engaged in R&D, underscoring the company's focus on pioneering advancements in the field.
The impact of MGI's work is further evidenced by the publication of over 6,800 papers in prestigious scientific journals, showcasing the significant contribution of MGI's technology to the scientific community and beyond.
For more information about MGI and its contributions to life science and healthcare, please visit the MGI website or connect with us on Twitter, LinkedIn, or YouTube.
Genomics Innovation
Single-Cell Sequencing
Life Science Collaboration
RNA-Sequencing Technology
Precision Medicine Tools
Share this article :
Share
More Testimonies
Aug 7, 2023
A Holistic Approach to Precision Medicine with Zhengming Chen
Dive into Zhengming Chen's insights on advancing precision medicine through a comprehensive approach to health, disease control, and prevention, highlighting the significance of global collaboration and diverse population studies.
Aug 7, 2023
Advancing Viral Sequencing: Insights from Teresa Cutino Moguel and MGI's Role
Teresa Cutino Moguel shares her insights into viral sequencing, its importance in patient care, challenges, and the role of technology at MGI-Tech. She emphasizes the need for accessibility, representation in science, and how collaborations during the pandemic have fostered growth in the field.
Aug 7, 2023
The Human Protein Atlas and Precision Medicine: A Conversation with Mathias Uhlen
Delve into Mathias Uhlen's journey with the Human Protein Atlas, uncovering the potential of precision medicine to transform healthcare, backed by groundbreaking research and technological advancements.